Entries by Zeeshan Khan

Emergence of Group A Streptococcal Diseases: From Strep Throat to Invasive Infections

Group A Streptococcus (group A strep, Streptococcus pyogenes), is a bacterium responsible for a range of infectious diseases. From the common strep throat to more serious invasive infections, the emergence of group A Streptococcal diseases poses a significant health concern worldwide. Understanding Strep Throat Strep throat is a common and highly contagious infection that primarily […]

Candida auris: Infections and Diagnostic Challenges

Candida auris, a relatively new and emerging fungal pathogen, has caused significant concern in recent years. Since its discovery in 2009, this elusive pathogen has become a global health threat due to its ability to spread rapidly and its resistance to common antifungal medications. The rise of C. auris infections has been alarming. Initially identified […]

Understanding the Threat of Invasive Fungal Infections: Causes, Symptoms, and Diagnosis

Invasive fungal infections present a formidable challenge in the realm of healthcare, posing significant risks to individuals with compromised immune systems or underlying health conditions. These infections, caused by various fungi, can manifest in diverse forms, ranging from superficial skin infections to life-threatening systemic diseases. Understanding the nature of invasive fungal infections, their causes, symptoms, […]

December 2023 Update: BioGX in silico analysis of SARS-CoV-2 variants of interest and emerging variants

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants. BioGX has completed in silico analysis of over 290,000 complete high coverage Omicron genomes of sublineages belonging to the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades present in the […]

BioGX Expands PCR Test Menu at State Departments of Health

BIRMINGHAM, AL / January 11, 2024 / BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health (DoH) with the addition of its Candida auris assay. BioGX currently services 6 DoH agencies with expansion to 10 agencies expected in Q1 2024. “We are […]

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc. (“BioGX”), a global provider of easy molecular diagnostic solutions. The companies are collaborating to make Microbix’s Quality Assessment Products (“QAPs™”) available to BioGX […]

BioGX in silico analysis of recent update on a surge of SARS-CoV-2 Omicron variant strains

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants. BioGX has completed in silico analysis of over 44,000 complete high coverage Omicron genomes of sublineages belonging to the EG.5, EG.5.1, BA.2.86, and XBB.1.9.1 (including FL.1.5.1) present in the Global Initiative on Sharing […]